Clinical Trials
24 trialsNCT06399029 2026-04-30
TRUX-LST
University of Zurich
Phase 2 Active not recruiting
NCT07476807 2026-04-28
TREATS
Sligo General Hospital
Phase NA Enrolling by invitation
NCT07426822 2026-02-24
SAFE-CAP
Yale University
Phase 2 Not yet recruiting
NCT03363763 2025-12-01
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
Aucta Pharmaceuticals, Inc
Phase 2 Terminated
NCT07021495 2025-08-19
SKINERGY
Leiden University Medical Center
Recruiting
NCT01880515 2025-05-11
Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)
Instituto Nacional de Cancerologia de Mexico
Phase 2 Completed
NCT03992664 2025-02-13
Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.
Cyprus University of Technology
Phase NA Completed
NCT05966584 2024-08-29
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04878692 2021-05-07
OPERA
Hospices Civils de Lyon
Phase NA Unknown
NCT03440515 2020-01-07
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Completed
NCT02239731 2018-02-27
Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients
Vyne Therapeutics Inc.
Phase 2 Completed
NCT01136005 2017-11-13
BeCet
Impaqtt Foundation
Phase 3 Completed
NCT00473083 2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2 Completed
NCT01931150 2017-01-13
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00332163 2016-02-23
STEPP
Amgen
Phase 2 Completed
NCT00803842 2015-02-26
Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash
Northwestern University
Phase NA Withdrawn
NCT01315990 2013-12-18
DERMATUX
Johannes Gutenberg University Mainz
Phase 4 Unknown
NCT01466504 2013-04-15
Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin
Dartmouth-Hitchcock Medical Center
Terminated
NCT01299220 2013-01-16
Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
University of Pittsburgh
Phase 4 Withdrawn
NCT01196468 2012-04-12
HIV Indicator Diseases Survey Across Europe - UK Arm
Chelsea and Westminster NHS Foundation Trust
Unknown
NCT01380262 2011-06-27
STLDD-1
Maria Sklodowska-Curie National Research Institute of Oncology
Unknown
NCT00343187 2011-05-30
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
Allergan
Phase 2 Terminated
NCT00610818 2008-02-08
Palifermin
McGill University Health Centre/Research Institute of the McGill University Health Centre
Terminated
NCT00158041 2005-09-12
Subcutaneous Amifostine Safety Study
Mt. Sinai Medical Center, Miami
Phase 4 Completed